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Abstract
Background: Visual hallucinations are common in patients with Parkinson’s disease
and represent probably the major independent predictor for cognitive deterioration
and nursing home placement.
Objective: To investigate if treatment of minor visual hallucinations in Parkinson’s dis-
ease with rivastigmine delays the progression to psychosis.
Methods: A multicenter, randomized, double-blind, placebo-controlled trial was con-
ducted which aimed to recruit 168 patients with Parkinson’s disease reporting minor
visual hallucinations 4 weeks before it. Important exclusion criteria were Parkinson’s
disease dementia, current delirium, and treatment with antipsychotics or drugs that
have significant anti-cholinergic sideeffects. Subjectswere randomized to rivastigmine
capsules, 3–6 mg twice a day, or placebo for 24 months. The primary outcome was
the time to Parkinson’s disease psychosis, which was defined as the need to start with
antipsychotics.
Results: The trial was stopped prematurely because of slow recruitment. Ninety-one
patients were randomized: 46 patients were assigned to rivastigmine and 45 patients
to placebo. No effect of rivastigmine could be demonstrated on the transition time to
psychosis or dementia during the 24-month follow-up period. After 6 months of study
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treatment, cognition, mood, motor performance, and non-motor performance did not
differ significantly between the rivastigmine-group and the placebo-group.
Conclusions: Because the study was terminated early, it was insufficiently powered to
properly evaluate the primary outcome. The limited data of the study favor a wait and
see approach instead of early treatment with rivastigmine in PD patients with minor
VH.
KEYWORDS
cholinesterase inhibitors, hallucinations, Parkinson’s disease, psychosis, randomized controlled
trial
1 INTRODUCTION
Visual hallucinations (VH) are common in patients with Parkinson’s
disease (PD) and represent probably the major independent predic-
tor for cognitive deterioration and nursing home placement (Diederich
et al., 2009; Kempster et al., 2010). Many patients present with minor
VH, including presence or passage phenomena, which over time often
progress to major VH with well-formed images and psychosis with
delusions, where there is loss of insight into the false nature of these
hallucinations and beliefs (Goetz et al., 2006).
Retrospective data suggest that early treatment of minor VH with
clozapine can delay the transition to psychosis (Goetz et al., 2008).
However, many regard clozapine unsuitable for long-term use in PD
because of the risk for serious side effects, such as agranulocytosis,
orthostatic hypotension, and sedation (Wang et al., 2005; The Parkin-
son Study Group, 1999).
Cholinesterase inhibitors are a recommended treatment of PD
dementia and might be a potential alternative to clozapine for the
treatmentofVH (Seppi et al., 2019). A large randomized controlled trial
of rivastigmine demonstrated that both cognition and behavior were
improved at a group level in patients with PD dementia (Emre et al.,
2004). Furthermore, a post hoc analysis reported a greater therapeutic
benefit for those PD dementia patients who also experience VH (Burn
et al., 2006).
We initiated a clinical trial to investigate whether the treatment of
minor VHwith rivastigmine delays the progression to PD psychosis. In
addition, we anticipated to confirm an immediate effect on the severity
of VH. Unfortunately, the trial had to be stopped prematurely, because
of slow recruitment.We present the results of the trial according to an
adapted version of the original statistical analysis plan.
2 METHODS
2.1 Trial overview
We conducted a multicenter, randomized, double-blind, placebo-
controlled trial. The ethics committee of the Amsterdam University
Medical Centers in the Netherlands approved the protocol. The trial
was conducted in accordance with the principles of the Declaration
of Helsinki. The trial was registered on http://www.clinicaltrials.gov
(NCT01856738). Trial monitoring and data management were per-
formed in accordance with the International Conference on Harmoni-
sationGoodClinical Practice guidelines. All the patients providedwrit-
ten informed consent. An independent Data and Safety Monitoring
Board (DSMB)monitored safety and efficacy data.
2.2 Patients
The inclusion criteria were PD according to diagnostic criteria (Hughes
et al., 1992) in the last 4 weeks minor VH defined by a score of 1 or
2 on the hallucinations item of the Movement Disorders Society Uni-
fied Parkinson’s Disease rating Scale (MDS-UPDRS; Goetz et al., 2008)
and age 40 years and above. Important exclusion criteria were delir-
ium, PD psychosis (defined as treatment with antipsychotic drugs), PD
dementia (defined as MMSE-score < 26 at baseline), treatment with
cholinesterase inhibitors in the past 6 months, and VH that appeared
within 1 month following the increase of dopaminergic treatment. We
also excluded subjects taking drugswith significant anticholinergic side
effects (including amantadine), subjects with a history of PD psychosis
and subjectswho stayed permanently in a nursing home. Subjectswere
recruited from30 community hospitals and 7 academic hospitals in the
Netherlands.
2.3 Trial procedures
After the baseline assessment (visit 1), subjectswere randomized using
a centralized web-based application in a 1:1 ratio to receive rivastig-
mine (rivastigmine-group) or placebo (placebo-group). Randomization
was stratified by type of hospital (University Medical Center versus
non-University Medical Center) and age (below 65 years or 65 years
and older) using variable permuted blocks. Study personnel, research
nurses, neurologists, and subjects were blinded to the treatment allo-
cation until the database was locked.
Rivastigmine dosage was increased according to a standardized
titration schedule in the first 12 weeks from 1.5 mg capsules to the
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maintenance dose of 6.0 mg capsules BID. Masking was achieved
with matched placebo capsules and a dummy up titration schedule. In
case of persisting side effects, the dose was lowered. The subject was
instructed to keep the highest tolerated dose until the end of the study
with a minimum of rivastigmine 3.0 mg BID. The treatment started as
soon as possible after randomization (with amaximumof 6weeks after
visit 1).
Four specified follow-up visits (at home or at the outpatient clinic)
were planned at 6, 12, 18, and 24 months after the start of treatment
(visits 2, 3, 4, and 5, respectively). In addition, subjects were asked
about side effects in a telephone interview during the titration period
(after 2, 3, 5, 8, and 11weeks of treatment).
If a subject developed PD psychosis (primary endpoint), the study
medication was discontinued and an extra visit was scheduled within
6 weeks if the subject was still able to perform tests. Planned visits,
except the last visit (visit 5), were cancelled after the primary endpoint
was reached.
If a subject met the criteria for PD dementia (secondary endpoint),
the subject was instructed to stop taking the study medication. Sub-
sequently, rivastigmine was prescribed by the treating neurologist
according to the current guideline (Rogers et al., 2017). This secondary
endpoint was added after the trial started because subjects turned out
to convert todementia before converting topsychosis and rivastigmine
is considered the standard care for PD dementia.
2.4 Outcome measures
The primary outcome was the time to PD psychosis observed during
the 24-months follow-up period. PD psychosis was defined as a behav-
ior that required the use of antipsychotics according to the treating
neurologist. Secondary outcomes included the time to PD dementia,
diagnosed by the treating neurologist according to current guidelines
(disability in> 1 cognitive domain and a score< 26 on theMini Mental
State Examination; Emre et al., 2007). Other secondary outcomes,
assessed at 6-month, were: severity of PD symptoms (MDS-UPDRS
part 1–3; Goetz et al., 2008) psychotic symptoms (Scale to Assess
Positive Symptoms; Andreasen, 1990) cognitive function (Montreal
Cognitive Assessment; Parkinson’s Disease Cognitive Rating Scale;
Nasreddine et al., 2005; Pagonabarraga et al., 2008) mood (Hospital
Anxiety and Depression Scale; Zigmond & Snaith, 1983) daytime
sleepiness (Epworth Sleepiness Scale; Johns, 1991) disability (AMC
Linear Disability Score; Weisscher et al., 2007) adverse events, and
compliance to study treatment.
2.5 Sample size calculation
Based on two retrospective studies that investigated early treatment
of VH with clozapine and presuming an exponential disease course
we assumed that within the 24-month follow-up period 35% of the
subjects in the placebo-group would not reach the primary endpoint
(PD psychosis) versus 60% in the rivastigmine-group (Goetz et al.,
2006; Goetz et al., 2008). With a sample size in each group of 63
subjects (126 in total), a 0.05 level two-sided log-rank test for equal-
ity of survival curves would have 80% power to detect the difference
between the placebo-group proportion at 24 months of 0.35 (propor-
tion of subjects without psychosis) and the rivastigmine-group propor-
tion at 24 months of 0.60 (proportion of subjects without psychosis),
with a constant hazard ratio of 2.055. Anticipating a dropout rate of
25%, we needed 63/0.75 = 84 subjects per treatment group (168 in
total).
2.6 Statistical analysis
Analyseswere based on the intention-to-treat principle. Baseline char-
acteristics and outcome parameters, including adverse events, were
summarized using descriptive statistics. The main analysis of this trial
consisted of a univariate comparison between the treatment groups
for the primary outcome within a 24-month follow-up period. The
between-group difference in time until subjects progressed to PD psy-
chosis was analyzed by plotting Kaplan–Meier curves and comparing
them using the log-rank test. The same statistical approach was used
with regard to the between-group difference in time to PD demen-
tia (secondary outcome). With regard to the remaining secondary
outcomes on cognition and behavior (MDS-UPDRS part 1–3, SAPS,
MoCA, PD-CRS, HADS, ESS, ALDS) we compared the change scores
(frombaseline to 6-month follow-up) between treatment groups, using
the Pearson’s Chi-squared (χ2) test, Welch’s two sample t-test, and
Wilcoxon rank sum test (with continuity correction), where appropri-
ate. A two-sided p value less than .05 was considered statistically sig-
nificant.We did not correct for multiple testing.
3 RESULTS
3.1 Subjects
From November 2013 through December 2017, 292 subjects were
screened for participation in the study. Ninety-one subjects were
enrolled and randomized; 46 subjects were assigned to rivastigmine
and 45 to placebo (Figure 1). Baseline demographic and clinical char-
acteristics of the two groupswere comparable (Table 1). From the start
of the trial, recruitment was slow despite numerous efforts to increase
the inclusion rate. After an inclusion period of three-and-a-half years,
the DSMB performed an interim futility analysis on the primary out-
come with a total of 80 included patients (39 assigned to rivastigmine
and 41 to placebo). The DSMB concluded that the trial did not seem
to be futile and advised to continue the study. Despite new strate-
gies, the inclusion rates again had not improved during the six months
after the interim analysis. Eventually the study group decided that it
was no longer feasible to achieve the original study target. In con-
sultation with the funding partners, the trial was ended prematurely.
Thirty-four patients in the rivastigmine-group and 37 patients in the
placebo-group completed the 6-month follow-up period. Twenty-one
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F IGURE 1 Enrollment and randomization
patients in the rivastigmine-group and 18 patients in the placebo-
group completed the 24-month follow-up period (Figure 1).
3.2 Outcomes
Figure 2 presents the between-group difference in time to PD psy-
chosis (primary outcome). No significant difference between the sur-
vival curves could be demonstrated (p = .70; log-rank test). In the
rivastigmine-group, 4 out of 46 subjects developed PD psychosis, and
in the placebo-group 5 out of 45 developed PD psychosis.
Between-group difference in time to PD dementia (secondary out-
come) is depicted in Figure 3. No significant difference between the
curves was observed (p = .20). In the rivastigmine-group, 4 out of 46
subjects developed PD dementia and in the placebo-group 1 out of 45
developed PD dementia.
After 6 months of treatment, there were no statistically signifi-
cant differences in change scores between the treatment groups on
the MDS-UPDRS part 1 (p = 0.98; Wilcoxon rank sum test), MDS-
UPDRS part 2 (p = 0.71; Wilcoxon rank sum test), MDS-UPDRS part
F IGURE 2 Primary outcome: time in days before visual
hallucinations progress to Parkinson’s disease psychosis
(Kaplan–Meier curve)
VANMIERLO ET AL. 5 of 9






Mean age in years± SD 66.9± 7.9 66.6± 8.0
Number aged 65 years or older (%) 29 (63%) 28 (62%)
Number of women (%) 14 (30%) 12 (27%)
Years since diagnosis± SD 8.0± 5.2 5.9± 4.3
Years since onset of visual
hallucinations± SD
2.2± 2.8 2.3± 2.7
Number recruited from university
hospital (%)
13 (28%) 12 (27%)
MDS-UPDRS scorea
Mean part 1± SD 15.4± 6.7 14.2± 4.4
Mean part 2± SD 14.3± 7.9 14.2± 5.9
Mean part 3± SD 30.7± 17.1 34.9± 12.1
MedianMMSE (range)b 29 (26–30) 29 (26–30)
MedianMoCa (range)c 24 (19–30) 25 (16–30)
Median HADS (range)d 10 (0–33) 11 (0–42)
Abbreviations: HADS, Hamilton anxiety and depression Score; MDS-
UPDRS, movement disorders society unified Parkinson’s disease rating
scale; MMSE, mini-mental sate examination; MoCa, Montreal Cognitive
Assessment.
aMDS-UPDRS scores range from 0 to 176, with higher scores indicating
more severe disease; the scale includes subscales of mental function (part
1, range 0–52), activities of daily living (part 2, range 0–52) andmotor func-
tion (part 3, range 0–132).
bMMSE scores range from0 to 30, with lower scores indicating greater cog-
nitive impairment.
cMoCa scores range from 0 to 30, with lower scores indicating greater cog-
nitive impairment.
dHADS scores range from0 to42,with higher scores indicatingmore severe
affective symptoms.
F IGURE 3 Secondary outcome: time in days before visual
hallucinations progress to Parkinson’s disease dementia
(Kaplan–Meier curve)
3 (p = 0.54; Wilcoxon rank sum test), SAPS (p = 0.13; Welch’s t-test);
MoCA (p = 0.28; χ2 test), PD-CRS (p = 0.75; Welch’s t-test), HADS
(p = 0.83; Welch’s t-test), ESS (p = 0.97 Welch’s t-test), and ALDS
(p= 0.06;Welch’s t-test; Figure 4).
The subjects in the rivastigmine-group stopped study medication
more often compared to the subjects in the placebo-group (20 out of
46 and 7 out of 45, respectively). The majority of subjects stopped
with the study medication within the first six months (15 of 20 and
5 of 7, respectively; Figure 5). Adverse events reported in the first
threemonths formed a likely explanation. In the first 12weeks, gastro-
intestinal symptoms (in particular nausea, vomiting, and diarrhea)
seemed to occur more frequently in the rivastigmine-group compared
to the placebo-group. Notably, nauseawas reportedmore often during
the early titration phase (week 3) in the placebo-group.
4 DISCUSSION
We investigated the merits of early treatment of minor VH in PD with
rivastigmine. Only few prior, single-center trials studied rivastigmine
in a non-demented PD population and although the final sample size
of our multicenter trial was relatively small and well below our pre-
defined targets, it is one of the largest to date and with good exter-
nal validity (Henderson et al., 2016;Mamikonyan et al., 2015). The trial
was terminated prematurely due to slow recruitment. Therefore, the
hypothesis that cholinesterase inhibitors, when given to patients with
PD who experience VH, can delay the progression to PD psychosis
could neither be confirmed nor firmly rejected. In addition, we could
not demonstrate benefit from rivastigmine treatment after six months
on any of the secondary outcome measures: (non)-motor symptoms,
psychotic symptoms, cognition, mood, daytime sleepiness, or disabil-
ity. This agrees with previous research on the use of rivastigmine in
patients with PD andmild cognitive impairment showing no advantage
on behavioral symptoms (Mamikonyan et al., 2015). Taken together,
this suggests that rivastigmine only improves behavioral outcomes in
patients with established PD dementia (Emre et al., 2004).
In our study, the number of patients that converted from having
minorVHtoPDpsychosis in our randomized controlled trialwas rather
low (9 out of 91 subjects converted in 2 years) when compared to the
retrospective cohort-study by Goetz and colleagues (39 out of 48 sub-
jects converted in 3 years; Goetz et al., 2006), possibly because we
included patients that experienced VH only once per month, and were
not necessarily troubled by these hallucinations. Interestingly, 10% of
thepatients thatwere referred and screened for the trial could not par-
ticipate because they had a VH frequency of less than one per month.
However, it should be noticed that the frequency of the VH is difficult
to determine: the experience is not only subjective, but often also brief
and not always reported or remembered. In addition, an ongoing taboo
to discuss hallucinations in the consulting room also may influence the
real prevalence rate of VH. Taking this together, the amount of suit-
able candidates for recruitment in the present studywas unfortunately
rather low (Fénelon et al., 2000).
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F IGURE 4 Secondary outcomes: differences in scores change after six months of treatment
Slow recruitment can also be the result of a limited interest in the
trial. First, patients do not consider their VH debilitating. Second, neu-
rologists already prescribe rivastigmine off label to reduce trouble-
some VH in PDwithout dementia.
After appropriate counseling, potentially eligible subjects found
the trial to be rather burdening. They opted out as they were con-
cerned that drug treatment would worsen their overall performance.
Furthermore, we wrongly assumed that PD patients would be con-
vinced about the positive effect on quality of daily life of drug treat-
ment. In the absence of a short-term gain, the 24-month follow-
up period might have been too intensive for this fragile target
population.
As mentioned before, the dropout rates were high and treatment
compliance was low. This might have affected the outcome negatively.
Earlier reports provided different findings on rivastigmine treatment
withdrawal and the number of (gastro-intestinal) adverse events. Our
trial is not the first to find a 40% discontinuation rate and around 30%
gastro-intestinal side effects approximately (Henderson et al., 2016).
The total number of side effects in the rivastigmine-group was higher
than in the placebo-group. The low tolerance for oral medication and
consequently low dosages used may have been a further limiting fac-
tor that could explain whywe found no significant benefits for rivastig-
mine treatment, not evenon cognitive functioning. Transdermal admin-
istration of rivastigmine probably would have led to a lower dropout
rate and higher mean maintenance dose (Emre et al., 2014). However,
it is possible that patients require an obvious, immediate benefit to
improve long-term compliance, sufficiently to test for possible long-
term effects.
In summary, the limited data of our study favor a wait and see
approach instead of early treatment with rivastigmine in PD patients
with minor VH. Minor VH in PD patients are difficult to measure, are
not always considered debilitating and progresses slowly. Compliance
with rivastigmine as a preventive treatment is low. We did not find
a reason to start rivastigmine treatment before the criteria for PD
dementia are met. This is in accordance with the current guidelines
(Connolly & Lang, 2014; Rogers et al., 2017; Seppi et al., 2019).































F IGURE 5 Compliance
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